Aspen Pharmacare Holdings Ltd banner
A

Aspen Pharmacare Holdings Ltd
JSE:APN

Watchlist Manager
Aspen Pharmacare Holdings Ltd
JSE:APN
Watchlist
Price: 13 194 Zac 1.49% Market Closed
Market Cap: 58.9B ZAR

Multiples-Based Value

The Multiples-Based Value of one APN stock under the Base Case scenario is 20 122.49 Zac. Compared to the current market price of 13 194 Zac, Aspen Pharmacare Holdings Ltd is Undervalued by 34%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APN Multiples-Based Value
Base Case
20 122.49 Zac
Undervaluation 34%
Multiples-Based Value
Price
A
Worst Case
Base Case
Best Case

Multiples Across Competitors

APN Competitors Multiples
Aspen Pharmacare Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ZA
Aspen Pharmacare Holdings Ltd
JSE:APN
58.6B ZAR 1.5 -29.3 -128.8 -128.8
US
Eli Lilly and Co
NYSE:LLY
847.5B USD 13 41.1 27.7 29.6
US
Johnson & Johnson
NYSE:JNJ
576.1B USD 6.1 21.5 14.9 18.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.4 12.9
US
Merck & Co Inc
NYSE:MRK
294.3B USD 4.5 16.1 10 12.1
UK
AstraZeneca PLC
LSE:AZN
218.1B GBP 4.9 28.1 15.6 22
CH
Novartis AG
SIX:NOVN
229.5B CHF 5.2 21.1 13.1 16.8
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
156.8B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 2.5 17 7.2 8.8
P/E Multiple
Earnings Growth PEG
ZA
A
Aspen Pharmacare Holdings Ltd
JSE:APN
Average P/E: 21.6
Negative Multiple: -29.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.1
14%
1.2
UK
AstraZeneca PLC
LSE:AZN
28.1
26%
1.1
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
20.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ZA
A
Aspen Pharmacare Holdings Ltd
JSE:APN
Average EV/EBITDA: 49.1
Negative Multiple: -128.8
14%
N/A
US
Eli Lilly and Co
NYSE:LLY
27.7
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
CH
Novartis AG
SIX:NOVN
13.1
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ZA
A
Aspen Pharmacare Holdings Ltd
JSE:APN
Average EV/EBIT: 108.1
Negative Multiple: -128.8
4%
N/A
US
Eli Lilly and Co
NYSE:LLY
29.6
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
UK
AstraZeneca PLC
LSE:AZN
22
21%
1
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett